These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 23649185)

  • 1. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials.
    Ford AC; Peyrin-Biroulet L
    Am J Gastroenterol; 2013 Aug; 108(8):1268-76. PubMed ID: 23649185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease.
    Luthra P; Peyrin-Biroulet L; Ford AC
    Aliment Pharmacol Ther; 2015 Jun; 41(12):1227-36. PubMed ID: 25903741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease.
    Williams CJ; Peyrin-Biroulet L; Ford AC
    Aliment Pharmacol Ther; 2014 Mar; 39(5):447-58. PubMed ID: 24444171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.
    Ford AC; Sandborn WJ; Khan KJ; Hanauer SB; Talley NJ; Moayyedi P
    Am J Gastroenterol; 2011 Apr; 106(4):644-59, quiz 660. PubMed ID: 21407183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD: A Systematic Review and Meta-analysis.
    Shah ED; Farida JP; Siegel CA; Chong K; Melmed GY
    Inflamm Bowel Dis; 2017 Apr; 23(4):570-577. PubMed ID: 28230558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
    Lawrance IC; Radford-Smith GL; Bampton PA; Andrews JM; Tan PK; Croft A; Gearry RB; Florin TH
    J Gastroenterol Hepatol; 2010 Nov; 25(11):1732-8. PubMed ID: 21039834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis.
    Ford AC; Bernstein CN; Khan KJ; Abreu MT; Marshall JK; Talley NJ; Moayyedi P
    Am J Gastroenterol; 2011 Apr; 106(4):590-9; quiz 600. PubMed ID: 21407179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse symptoms with anti-TNF-alpha therapy in inflammatory bowel disease: systematic review and duration-response meta-analysis.
    Wang F; Lin X; Zhao Q; Li J
    Eur J Clin Pharmacol; 2015 Aug; 71(8):911-9. PubMed ID: 26022220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Varicella zoster exposure in patients with inflammatory bowel disease--recall is not enough.
    Aggarwal D; Limdi JK
    Am J Gastroenterol; 2014 Mar; 109(3):448-9. PubMed ID: 24594962
    [No Abstract]   [Full Text] [Related]  

  • 10. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
    Van Assche G; Lewis JD; Lichtenstein GR; Loftus EV; Ouyang Q; Panes J; Siegel CA; Sandborn WJ; Travis SP; Colombel JF
    Am J Gastroenterol; 2011 Sep; 106(9):1594-602; quiz 1593, 1603. PubMed ID: 21844919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF-α Antagonists.
    McConachie SM; Wilhelm SM; Bhargava A; Kale-Pradhan PB
    Ann Pharmacother; 2018 Jun; 52(6):571-579. PubMed ID: 29363355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.
    Salmon-Ceron D; Tubach F; Lortholary O; Chosidow O; Bretagne S; Nicolas N; Cuillerier E; Fautrel B; Michelet C; Morel J; Puéchal X; Wendling D; Lemann M; Ravaud P; Mariette X;
    Ann Rheum Dis; 2011 Apr; 70(4):616-23. PubMed ID: 21177290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease.
    Ma C; Lee JK; Mitra AR; Teriaky A; Choudhary D; Nguyen TM; Vande Casteele N; Khanna R; Panaccione R; Feagan BG; Jairath V
    Aliment Pharmacol Ther; 2019 Jul; 50(1):5-23. PubMed ID: 31119766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis.
    Billioud V; Ford AC; Tedesco ED; Colombel JF; Roblin X; Peyrin-Biroulet L
    J Crohns Colitis; 2013 Dec; 7(11):853-67. PubMed ID: 23523418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.
    Bongartz T; Sutton AJ; Sweeting MJ; Buchan I; Matteson EL; Montori V
    JAMA; 2006 May; 295(19):2275-85. PubMed ID: 16705109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease.
    Shale MJ; Seow CH; Coffin CS; Kaplan GG; Panaccione R; Ghosh S
    Aliment Pharmacol Ther; 2010 Jan; 31(1):20-34. PubMed ID: 19681818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of infections associated with biological treatment in inflammatory bowel disease.
    Andersen NN; Jess T
    World J Gastroenterol; 2014 Nov; 20(43):16014-9. PubMed ID: 25473153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis.
    Ford AC; Kane SV; Khan KJ; Achkar JP; Talley NJ; Marshall JK; Moayyedi P
    Am J Gastroenterol; 2011 Apr; 106(4):617-29. PubMed ID: 21407190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.